• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Palvella Therapeutics, Inc. - Common Stock (NQ:PVLA)

    118.18 -2.21 (-1.84%)
    Streaming Delayed Price Updated: 10:28 AM EDT, Mar 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 36,338
    Open 117.57
    Bid (Size) 116.34 (100)
    Ask (Size) 120.00 (100)
    Prev. Close 120.39
    Today's Range 113.99 - 118.71
    52wk Range 18.23 - 151.18
    Shares Outstanding 98,935,025
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal ↗
    This clinical-stage biotech advancing therapies for rare skin diseases reported a notable insider sale amid a year of sharp stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win ↗
    Focused on therapies for rare skin diseases, this clinical-stage biotech saw a notable director purchase coincide with a decisive Phase 3 trial announcement and the closing of a $230 million equity... 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +17.9%
    +17.9%
    1 Month
    +34.5%
    +34.5%
    3 Month
    +11.7%
    +11.7%
    6 Month
    +100.7%
    +100.7%
    1 Year
    +333.4%
    +333.4%

    More News

    Read More
    News headline image
    Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Pricing of Upsized Public Offering
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Proposed Public Offering
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Palvella Therapeutics Inc (NASDAQ:PVLA) Reports Q3 2025 Earnings Miss, Highlights Key Clinical Milestones ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Palvella Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 11, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is Palvella Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Palvella Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Palvella Therapeutics, Inc. - Common Stock trade on?
    Palvella Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Palvella Therapeutics, Inc. - Common Stock?
    The ticker symbol for Palvella Therapeutics, Inc. - Common Stock is PVLA on the Nasdaq Stock Market
    What is the current price of Palvella Therapeutics, Inc. - Common Stock?
    The current price of Palvella Therapeutics, Inc. - Common Stock is 118.18
    When was Palvella Therapeutics, Inc. - Common Stock last traded?
    The last trade of Palvella Therapeutics, Inc. - Common Stock was at 03/26/26 10:28 AM ET
    What is the market capitalization of Palvella Therapeutics, Inc. - Common Stock?
    The market capitalization of Palvella Therapeutics, Inc. - Common Stock is 11.69B
    How many shares of Palvella Therapeutics, Inc. - Common Stock are outstanding?
    Palvella Therapeutics, Inc. - Common Stock has 12B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.